Thromb-X is a Belgian

Belgium

Belgium , officially the Kingdom of Belgium, is a federal state in Western Europe. It is a founding member of the European Union and hosts the EU's headquarters, and those of several other major international organisations such as NATO.Belgium is also a member of, or affiliated to, many...

 biotech company. It was founded in 1991 by Professor Désiré Collen

Désiré Collen

Désiré Collen is a Belgian physician and chemist. He was born in Sint-Truiden, Belgium.-Education:He graduated as an M.D...

, an expert in cardiovascular disease, of the Katholieke Universiteit Leuven

Katholieke Universiteit Leuven

The Katholieke Universiteit Leuven is a Dutch-speaking university in Flanders, Belgium.It is located at the centre of the historic town of Leuven, and is a prominent part of the city, home to the university since 1425...

 and head of the VIB Departement of Transgene Technology and Gene Therapy, K.U.Leuven.

History

Thromb-X was founded in 1991, as a spin-off company of Katholieke Universiteit Leuven

Katholieke Universiteit Leuven

The Katholieke Universiteit Leuven is a Dutch-speaking university in Flanders, Belgium.It is located at the centre of the historic town of Leuven, and is a prominent part of the city, home to the university since 1425...

. The company was constituted jointly by K.U.Leuven R&D and Prof. Désiré Collen. In 2001 ThromboGenics Ltd., (Dublin, Ireland

Ireland

Ireland is an island to the northwest of continental Europe. It is the third-largest island in Europe and the twentieth-largest island on Earth...

), became the majority shareholder of Thromb-X and Thromb-X became the R&D subsidiary of Thrombogenics. From 2001-2007 Thromb-X was run by Managing Director Jean Marie Stassen Ph.D. In 2007 Thromb-X ceased to exists as an independent legal entity as it was absorbed by the publicly listed company Thrombogenics NV.

In that period Thromb-X advanced Staphylokinase, Microplasmin, TB-402 and TB-403 into clinical development.